Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-23-140697
Filing Date
2023-05-10
Accepted
2023-05-10 16:04:10
Documents
97
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d464631d10q.htm   iXBRL 10-Q 1915681
2 EX-10.1 d464631dex101.htm EX-10.1 3224
3 EX-31.1 d464631dex311.htm EX-31.1 10333
4 EX-31.2 d464631dex312.htm EX-31.2 10318
5 EX-32 d464631dex32.htm EX-32 4307
11 GRAPHIC g464631g66p75.jpg GRAPHIC 35356
12 GRAPHIC g464631teva2.jpg GRAPHIC 6543
  Complete submission text file 0001193125-23-140697.txt   10523372

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA teva-20230331.xsd EX-101.SCH 89206
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE teva-20230331_cal.xml EX-101.CAL 47660
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE teva-20230331_def.xml EX-101.DEF 565090
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20230331_lab.xml EX-101.LAB 583427
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20230331_pre.xml EX-101.PRE 596100
91 EXTRACTED XBRL INSTANCE DOCUMENT d464631d10q_htm.xml XML 2083509
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 5 BAZEL ST PO B 3190 PETACH TIKVA L3 49131
Business Address 5 BAZEL ST P O B 3190 PETACH TIKVA L3 49131 9729267267
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-16174 | Film No.: 23906255
SIC: 2834 Pharmaceutical Preparations